cyrilzakka/clinical-trials huggingface dataset:
Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)

This clinical trial is being conducted to 1) evaluate the possible usefulness of a panel of cardiac markers in assessing emergency department patients with possible acute coronary syndrome, 2) evaluate the usefulness of BNP in assessing emergency department patients with possible acute coronary syndrome, 3) determine if BNP can be used to predict adverse events during hospitalization and in the emergency department, and 4) evaluate how a Point-of-Care testing platform affects resource utilization in the emergency department.

The correct diagnosis of acute coronary syndrome (ACS) remains a frequent significant challenge for emergency physicians. Over eight million chest pain patients present annually and despite promising advances in diagnosis, over four percent of ACS patients are mistakenly discharged home. While the history and physical, cardiac risk factor assessment, ECG, and cardiac marker determination are all included in the assessment and risk stratification of patients presenting with possible ACS, this assessment is clearly far from perfect. Improved rapid and accurate means of assessment in this population in the ED are clearly needed.ED patients with chest discomfort will be screened and approached for study enrollment. Consenting patients meeting the study inclusion and exclusion criteria will be enrolled. Point-of-care serial cardiac marker measurements will be performed. Based on a web-based computerized randomization system, half (50%) the patients willundergo routine central laboratory testing only. Half (50%) of the patients will undergopoint-of-care markers performed in the ED in addition to routine central laboratory testing.In this second group, central laboratory test results will be blinded from the ED physicianuntil the disposition time. BNP will be blinded and not reported to physicians for the first 500 patients (Phase I). After the first 500 patients have been enrolled, an interim analysis will be performed to determine the clinical utility of BNP in patient assessment. After physician education of these results, the trial will resume for the remaining 500 patients (Phase II). In Phase II, BNP levels will be provided to the physicians using the same time and randomization format.The patients and their medical records will be followed for a period of thirty days and sixmonths after enrollment.

Eligibility Criteria:
Inclusion Criteria:

Age greater than or equal to 21 years at the time of enrollment Chest discomfort or other symptoms consistent with possible ACS as indicated by the treating physician obtaining an ECG and cardiac markers for the patient's evaluation New onset or worsening symptoms within six hours of presentation to the ED.

Exclusion Criteria:

History of CHF per patient history or in the available medical record. History of end stage renal disease on dialysis. Refused informed consent.4) Refused medical record review and telephone follow up at 30 days and six months.
Ventilation Strategy for the Elderly Patients in Prone Position

The investigators compare three ventilation modes; volume controlled ventilation, volume guaranteed pressure controlled ventilation and volume controlled ventilation with pause during spine surgery for the elderly patients. The investigators can reveal that how lung collapse can be reduced by optimizing the inspiratory flow pattern under general anesthesia.

\<Protocol\>

1. All patients were ventilated by an anaesthesia ventilator (Zeus, Dräger, Lübeck, Germany) under general anesthesia.
2. Ventilation strategy:

   * Pressure controlled ventilation volume guaranteed (PCV-VG) mode or volume control ventilation (VCV) mode
   * tidal volume 6-8 mL/kg (predicted body weight)
   * Inspiratory/expiratory (I/E) ratio 1:1.5
   * Inspired oxygen concentration (FIO2) 0.5 with air
   * 3.0 L/min of inspiratory fresh gas flow
   * Positive end-expiratory pressure (PEEP) of 5 cm H2O
   * Respiratory rate (RR) of 10 to 14 min-1
3. After prone positioning and hemodynamic condition was stabilized, patients were ventilated with VCV, PCV-VG mode, VCV with pause following a randomized order, previously determined for each patient. Before each ventilator setting was started, lung recruitment maneuvers were performed to set the lungs to a defined baseline status.

   * ventilation order : one of the following examples is taken by randomization.

VCV 15 min -- VCV pause 15min -- PCV-VG 15min

VCV 15 min -- PCV-VG 15min -- VCV pause 15min

VCV pause 15min -- VCV 15 min -- PCV-VG 15min

VCV pause 15min -- PCV-VG 15min -- VCV 15 min

PCV-VG 15min -- VCV 15 min -- VCV pause 15min

PCV-VG 15min -- VCV pause 15min -- VCV 15 min

Eligibility Criteria:
Inclusion Criteria:

* patients undergoing elective spine surgery under general anesthesia

Exclusion Criteria:

* obesity (body mass index \>35 kg/m2)
* chronic obstructive pulmonary disease
* respiratory infection
Osteoporosis and Fall Prevention With Multiple Interventions in the Metropolitan Area

OBJECTIVES To determine the effects of 3 exercise interventions on sarcopenic indices among community-dwelling older adults with high osteoporotic fracture risks.

MATERIAL AND METHOD The current study enrolled subjects who screened high risk of fall, osteoporosis/fracture by standardized questionnaires or FRAX. Subjects at the National Taiwan University Hospital Bei-Hu Branch (NTUHBB) were randomized into integrated care group (ICG, target n=50) and muscle training group (MTG, target n=50). Subjects from Lingko Chang Gung Memorial Hospital (LCGMH) were all assigned into X-box group (XBG, target n=30). All participants received a CD-ROM and a one education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, and coping strategy and another hour of professional led exercise program. ICG subjects received once weekly group exercise while MTG subjects received twice weekly machine-based resistence training on major muscle groups. XBG subjects rececived twice weekly exercise with X-box based programs. Major outcomes were muscle mass (measured by bio-impedance analysis), grip strength, walking speed, and lower leg extension power at baseline and after 12-weeks of intervention.


Eligibility Criteria:
Inclusion Criteria:

1. older than 50 years of age
2. high risk as defined from one of the following criteria:

   * score\>=1 on one minute osteoporosis risk questionnaire
   * 10 year predicted fracture risk \>=20% for major osteoporotic fracture or \>=3% for hip fracture from FRAX
   * fall\>=2 times in pass 1 year
3. having a bone mineral density test within one year period
4. having the capability to understand the study and complete the study interventions
5. willing to participate for the intervention and study follow ups

Exclusion Criteria:

1. People younger than 50 years of age
2. Could not communicate because of hearing, visual, or cognitive problems
3. Unable to stand and walk unaided (walking aids are acceptable)
The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients' Lipid Profiles

The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients


Eligibility Criteria:
Inclusion Criteria:

* Patient aged 20-65 years;either sex
* Patient diagnosed with hyperlipidemia(fasting levels of TC\>=200mg/dL),or TG\>=200mg/dL but \<400mg/dL,or LDL-C\>=130mg/dL)
* Patient who has signed the informed consent form

Exclusion Criteria:

* Patient with pregnancy (or child bearing potential),or in lactation
* Patient with any lipid regulating agents within 4 weeks prior to study period
* Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
* Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
* Patient with liver dysfunction (SGOT or SGPT\>2x ULN)
* Patient with renal insufficiency (serum creatinine\>1.3mg/dL)
* Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.
ScanBrit Dietary Intervention in Autism

A growing body of research indicates that dietary intervention excluding foods containing the proteins, gluten and casein, from the diet of children diagnosed with an autism spectrum disorder (ASD) may have a positive effect on behaviour and developmental outcome.

In this single-blind, randomised-controlled, matched-pair adaptive trial, we introduced a gluten- and casein-free (GFCF) diet to a group of pre-pubescent children diagnosed with ASD concurrently with an abnormal urinary profile. Following random allocation to a diet or non- diet group, stage 1 of the study saw an intervention group follow the GFCF diet for eight months initially - progressing to 12 months if required. A non-diet control group continued with a normal diet.

Assuming significant changes for the dietary group on the various outcome measures of behaviour and development, stage 2 of the study saw both groups assigned to GFCF dietary intervention for a further 12 months when outcome measures were again assessed at study end.

Eligibility criteria: diagnosis of autism, no co-morbid diagnosis of Fragile X syndrome, epilepsy or tuberous sclerosis, aged between 4-10y11m.

Experimental hypothesis: children with an autism spectrum disorder (ASD) on a GFCF diet would show a significantly improved group developmental outcome in the medium- and long-term with regards to core autism and/or secondary symptoms.

Main outcome measures: change in scores of dietary participants on one or more measures against predefined statistical thresholds as evidence of improvement, alongside changes to intra- and inter-group scores at study endpoint.

Main outcome measures ascertained by: Autism Diagnostic Observation Schedule (ADOS), Gillam Autism Rating Scale (GARS), Vineland Adaptive Behaviour Scales (VABS), Attention Deficit Hyperactivity Disorder - IV (ADHD-IV) scales.

Eligibility Criteria:
Inclusion Criteria:

* Autism Spectrum Disorder (ASD)
* Diagnosis received at Centre for Autism or a psychiatric clinic
* Abnormal urinary peptide profile

Exclusion Criteria:

* Medical treatment
* Epilepsy
Prevalance Of Helicobacter Pylori Infection In Chonic Kidney Diseased Patient Admitted To Luxor Medical Complex

Detect prevalence of Helicobacter pylori infection in chronic kidney diseased patient admitted to Luxor medical complex and possible role of Helicobacter pylori in pathogenesis of chronic kidney diseased patient of unknown etiology

Helicobacter Pylori bacteria is the main pathogenic organism that settles on the gastric mucosa of more than half the human population around the world, with more prominence in the developing countries. H. Pylori had been found to be the main factor in acute and chronic gastritis, peptic ulcer diseases, and in most cases gastric malignancy. Beside to some extra gastro-intestinal diseases. Such as cardiac, pulmonary, renal and hematological diseases.

Another study showed a significant higher proteinuria in H. Pylori infected patients compared to non-infected individuals. Helicobacter pylori is a gram-negative bacterium infecting both children and adults. It is the most common human chronic infection, causing gastrointestinal diseases such as gastric malignancies, gastritis, and ulcerative diseases. H. pylori can also be involved in other non gastrointestinal infections such as diabetes and metabolic syndrome, heart disease, hematologic disorders, cancer, and chronic kidney disease (CKD) as well as chronic renal failure (CRF).

Some chronic renal failure patients who have received hemodialysis for long periods complained of gastrointestinal troubles. It has been postulated that high urea concentration makes the gastric mucosa of these patients more susceptible to H. pylori colonization. Previous observations in different countries reported the prevalence of H. pylori infection among patients with CRF ranging between 20 and 60%, and H. pylori infection can contribute to progressive renal dysfunction resulting in CKD development. In patients without established gastric dysfunction, the presence of H pylori infection was associated with increased risk for Chronic kidney dusease however, patients with both atrophic gastritis (AG) and Helcobacter pylori infection appeared to be at decreased risk for Chronic kidney disease compared with control participants.

For the H. pylori-positive patients with peptic ulcer, H. pylori infection may be a risk factor resulting in kidney damage and H. pylori eradication probably benefits to kidney damage relief and chronic kidney disease prevention.

Eligibility Criteria:
Inclusion Criteria:

* All patients aged \>18 years old with chronic kidney disease of different etiology based on clinical examination, laboratory investigations and imaging

Exclusion Criteria:

1. Patients aged ≤18 years old.
2. Overloaded patients
3. patient with acute kidney injury
4. Patients with other GIT disease
5. pregnant female
6. patient taking aspirin, NSAID, steroid or antibiotic
7. Presence of malignancy
Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery

This is an observational and retrospective cohort study to evaluate the impact of the preoperative serum albumin concentration on postoperative outcomes among hepatocellular carcinoma (HCC) patients who received hepatectomy or liver transplantation.

The impact of hypoalbuminemia on postoperative outcomes has been the subject of several investigations which agreed that hypoalbuminemia is an important risk factor for mortality and morbidity after various types of surgical operations. Unfortunately, there are limited real-world data to establish the correlation between hypoalbuminemia and hepatectomy or liver transplantation postoperative complications in China. This study will evaluate the impact of the preoperative serum albumin concentration on postoperative outcomes among hepatocellular carcinoma (HCC) patients who received hepatectomy or liver transplantation.

Eligibility Criteria:
Inclusion Criteria:

* Patients who diagnosed with HCC confirmed by histology/cytology or clinically criteria regardless of gender.
* HCC Patients who had received the first hepatectomy or liver transplantation (LT).
* Age ≥18 years at the start date of the hepatectomy or LT.
* HCC patients who had the value of serum albumin within 7 days prior to the surgery.
* HCC patients who had exemption of informed consent.

Exclusion Criteria:

* HCC Patients with extrahepatic metastasis or other malignant tumours.
RCT of Air Insufflation Versus Water Infusion Colonoscopy

Compared with the conventional (air) method, patients examined by the study (water) method have lower pain scores and require less medication but have similar cecal intubation rate and willingness to repeat future colonoscopy.

Background: A novel water method permitted 52% of patients accepting on-demand sedation to complete colonoscopy without medications and significantly increased successful cecal intubation from 76% to 97% in patients accepting scheduled unsedated colonoscopy.

Aim: To perform a randomized controlled trial comparing air insufflation (conventional method) vs. water infusion in lieu of air (study method) colonoscopy in minimally sedated patients.

Hypothesis: Compared with the conventional method, patients examined by the study method have lower pain scores and require less medication but have similar cecal intubation rate and willingness to repeat future colonoscopy.

Setting: Outpatient colonoscopy in a single VA hospital Methods: After informed consent and standard bowel preparation, patients received pre-medications administered as 0.5 increment of Fentanyl (25 μg) and 0.5 increment of Versed (1 mg) plus 50 mg Diphenhydramine. The conventional and the study method for colonoscopy were implemented as previously described. Additional pain medications were administered at the patients' request.

Outcome measures: Increments of medications, pain scores, cecal intubation and willingness to repeat colonoscopy.

Limitations: Single VA site, older male population

Eligibility Criteria:
Inclusion Criteria:

* healthy individual 50 years or older
* eligible for colorectal cancer screening or surveillance

Exclusion Criteria:

* patients who do not understand or failed to sign informed consent
Study to Evaluate LPH-5 in Healthy Subjects

This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.


Eligibility Criteria:
Inclusion Criteria:

* Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, and clinical laboratory evaluations.

Exclusion Criteria:

* Any condition or disease detected during the medical interview/physical examination that could relapse during or immediately after the study, or would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the clinical study, as determined by the Investigator.
* Have a history of and/or current clinically significant determined by the Investigator
* Consumes cannabis or cannabis-derived compounds more than 3 times per month or has substantial changes in cannabis consumption in the 21 days prior to screening.
Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery

How does Lusedra compare with current standard of care (midazolam) for minimal to moderate sedation for regional anesthesia blocks prior to orthopedic surgery?

The study overall is aimed at establishing the superiority of a single intravenous bolus-dose of Lusedra for routine use in preoperative regional blocks that avoids deeper levels of sedation and increased risk of nerve damage in an over-sedated individual. The shorter half-life of Lusedra should also demonstrate a superior recovery profile compared to midazolam when used as a rescue comparator. While this study will only enroll patients undergoing regional blocks prior to orthopedic surgery, the clinical utility and value of the larger initial intravenous dosing for Lusedra may be evident for many different monitored anesthesia care anesthetic management situations requiring rapid and effective onset of effects.

Eligibility Criteria:
Inclusion Criteria:

* Undergoing elective orthopedic surgery
* With a regional block prior to surgery
* Able to consent and complete the assessments and procedures
* If female, must be surgically sterile, postmenopausal, or not pregnant or lactating and using an acceptable method of birth control for at least 1 month prior to surgery with a negative urine pregnancy test at screening
* American Society of Anesthesiologists Physical Classification System status category P1 to P4

Exclusion Criteria:

* History of allergic reaction or hypersensitivity to any anesthetic agent, opioid, or benzodiazepine
* Fentanyl citrate injection or midazolam hydrocholoride injection contraindicated
Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome

This is a virtual single group study that will last 12 weeks. Participants will take 1 scoop of the female hormone balance supplement, and mix it with their drink of choice every morning. Questionnaires will be completed at baseline, 1 week, 2 weeks, 4 weeks, and 12 weeks


Eligibility Criteria:
Inclusion Criteria:

* Women aged between 18 - 55
* BMI less than 35
* Self-reported concerns around irregular menstrual cycles and ovulation, mood swings, stress, irritability, and low energy
* Generally healthy - don't live with any uncontrolled chronic disease
* Self-reported symptoms of PCOS - irregular periods
* Self-reported concerns with hormonal skin issues

Exclusion Criteria:

* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
* Anyone with known severe allergic reactions
* Anyone who is pregnant, breastfeeding, or attempting to become pregnant
* Unwilling to follow the study protocol
Cell Responses to IFN-gamma

IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Normal volunteers with no evidence of skin disease OR diagnosis of plaque type psoriasis for at least 6 months
* 18 years of age or greater
* For women of childbearing potential or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study. Acceptable methods of contraception include use of a condom; abstinence; use by sexual partner of oral implantable or injectable contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap; or a sterile sexual partner

Exclusion Criteria:

* Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
* Clinically significant psoriasis flare during screening or on the first treatment day
* Hypersensitivity to IFN-g or E. coli derivatives
* Pre-existing, uncontrolled myelosuppression, cardiac disease, seizure disorders, compromised central nervous system function or multiple sclerosis
* History of malignancy, clinically significant renal insufficiency, poorly controlled medical conditions that would increase the risks
* Presence of malignancy within the past 5 years, including lymphoproliferative disorders. Subjects with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
* Pregnancy or lactation. As the risk of IFN-g in pregnancy is unknown, pregnant women will be excluded from the study.
* Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug